Revolution Medicines (RVMDW) Non-Current Deferred Tax Liability (2019 - 2026)
Revolution Medicines (RVMDW) posted quarterly Non-Current Deferred Tax Liability of $2.4 million for Q1 2026, little changed year-over-year from $2.4 million in Q1 2025, and little changed quarter-over-quarter from $2.4 million in Q4 2025.
Revolution Medicines (RVMDW) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends
Revolution Medicines' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (changed 0.0% YoY), while the FY2025 annual figure was $2.4 million, changed 0.0% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $2.4 million, roughly flat from $2.4 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $7.4 million in Q1 2022, with the low at $2.4 million in Q4 2024.
- The 5-year median for Non-Current Deferred Tax Liability is $3.1 million (2023), against an average of $4.3 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2022, then plunged 55.82% in 2023.
- Revolution Medicines' Non-Current Deferred Tax Liability stood at $7.0 million in 2022, then plunged by 55.66% to $3.1 million in 2023, then fell by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
- Business Quant data shows RVMDW's Non-Current Deferred Tax Liability at $2.4 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revolution Medicines | 2.45 Bn | 2.45 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Sep 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Jun 30, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |
| Mar 31, 2024 | 3.12 Mn |